Was the RXRX CFO share sale made under a Rule 10b5-1 plan?

Yes. The open-market sale of 13,426 shares at $3.08 per share was executed under a Rule 10b5-1 trading plan that Ben R. Taylor adopted on September 30, 2025, as noted in the Form 4 footnote.

What is the nature of the RXRX CFO’s tax-related share disposition?

The 11,908-share disposition was not a discretionary sale. The issuer withheld these shares to meet tax withholding and remittance obligations arising from the net settlement of restricted stock units held by the CFO.

RXRX CFO sells shares in planned 10b5-1 trade

RECURSION PHARMACEUTICALS, INC.

Accepted by SEC EDGAR 02/19/2026 - 07:30 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. Chief Financial Officer Ben R. Taylor reported two transactions in Class A common stock. On February 18, 2026, he completed an open-market sale of 13,426 shares at $3.08 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 1,195,349 shares owned directly.

On February 17, 2026, 11,908 shares were disposed of at $3.49 per share to cover tax withholding in connection with the net settlement of restricted stock units. These shares were withheld by the company to satisfy tax obligations rather than sold for discretionary portfolio reasons.

Insider Trade Summary

Net Seller: 13,426 shares

Net Sell 2 txns

Insider Taylor Ben R

Role Chief Financial Officer

Sold 13,426 shs ($41K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	13,426	$3.08	$41K
Exercise Price or Tax Liability	Class A Common Stock	11,908	$3.49	$42K

Holdings After Transaction: Class A Common Stock — 1,195,349 shares (Direct)

Footnotes (2)

F1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did RXRX CFO Ben R. Taylor report?

Ben R. Taylor reported an open-market sale of 13,426 Class A shares at $3.08 and a separate disposition of 11,908 shares at $3.49 to cover tax withholding from restricted stock unit settlement.

How many RXRX shares did the CFO sell in the open market?

The CFO sold 13,426 shares of Recursion Pharmaceuticals Class A common stock in an open-market transaction at $3.08 per share, as part of a pre-arranged Rule 10b5-1 trading plan filed with regulators.

How many RXRX shares does the CFO own after these transactions?

After the reported transactions, Ben R. Taylor directly owns 1,195,349 shares of Recursion Pharmaceuticals Class A common stock, according to the Form 4 ownership totals disclosed in the filing data.

Were any RXRX shares disposed of for tax withholding purposes?

Yes. 11,908 shares were withheld by Recursion Pharmaceuticals at $3.49 per share to satisfy tax withholding obligations tied to the net settlement of restricted stock units previously granted to the CFO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Ben R

(Last)

(First)

(Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY

84101

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	02/17/2026		F⁽¹⁾		11,908	D	$3.49	1,208,775	D
Class A Common Stock	02/18/2026		S⁽²⁾		13,426	D	$3.08	1,195,349	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR